Exelixis (EXEL) Curent Deferred Tax Liability (2011)

Exelixis (EXEL) posted quarterly Curent Deferred Tax Liability of $700000.0 for Q4 2011.

Analysis

Exelixis (EXEL) Curent Deferred Tax Liability (2011) Analysis & Trends

Exelixis' Curent Deferred Tax Liability history runs 1 years deep, the most recent figure standing at $700000.0 for Q4 2011.

In Q4 2011, Curent Deferred Tax Liability changed N/A year-over-year to $700000.0; the TTM figure through Dec 2011 stood at $700000.0 (changed N/A YoY), while the FY2011 annual figure was $700000.0, changed N/A from the prior year.
Curent Deferred Tax Liability for Q4 2011 stood at $700000.0.
The five-year high for Curent Deferred Tax Liability was $700000.0 in Q4 2011, with the low at $700000.0 in Q4 2011.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Curent Deferred Tax Liability (Qtr)
1	Vertex Pharmaceuticals	138.47 Bn	130.62 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	85.18 Bn	77.19 Bn	3.93 Bn	-
3	Argenx Se	63.38 Bn	58.19 Bn	1.37 Bn	-
4	Moderna	58.09 Bn	52.95 Bn	52.00 Mn	-
5	Revolution Medicines	44.33 Bn	44.33 Bn	-	-
6	BeOne Medicines	40.02 Bn	34.92 Bn	1.53 Bn	-
7	Alnylam Pharmaceuticals	35.57 Bn	32.27 Bn	992.69 Mn	-
8	Royalty Pharma	28.45 Bn	27.61 Bn	-	-
9	Insmed	27.48 Bn	26.32 Bn	358.27 Mn	-
10	Exelixis	14.81 Bn	13.97 Bn	608.03 Mn	-

Historic Data

Download Data

Date	Value
Dec 31, 2011	700,000.00